Home › Cases › Visible Haematuria
Visible Haematuria
Visible Haematuria
6 questions
Question 1 · Initial Assessment
Correct answer: Visible (macroscopic) haematuria — visible to the naked eye; painless visible haematuria is assumed to be due to urological malignancy until proven otherwise
Why
Haematuria is classified as: Visible (macroscopic/frank) — blood visible to the naked eye (as in Colin's case); or Non-visible (microscopic) — detected only on dipstick or urine microscopy (≥3 RBCs/HPF on microscopy). Painless visible haematuria is one of the most important urological red flags — it is assumed to be caused by urological malignancy (bladder cancer, renal cell carcinoma, transitional cell carcinoma of the upper ureter) until proven otherwise. Colin's ex-smoker status (30 pack-years) is a significant risk factor for bladder cancer (the most common urological malignancy). Painful haematuria is more suggestive of stones or UTI. Treating empirically with antibiotics without further investigation in a 68-year-old ex-smoker with painless visible haematuria is dangerous and could delay a cancer diagnosis.
Key point
Painless visible haematuria in an ex-smoker = urological malignancy until proven otherwise — this is a urology 2-week wait referral scenario; do not treat empirically with antibiotics.
Question 2 · Causes
Correct answer: Urological tumours (bladder, renal, upper tract TCC), urolithiasis, UTI/pyelonephritis, BPH, anticoagulation, trauma, renal causes (glomerulonephritis, IgA nephropathy), and exercise-induced haematuria
Why
A systematic approach to the differential diagnosis of visible haematuria includes: Malignancy — bladder carcinoma (most common in >50s, especially smokers), renal cell carcinoma (associated with haematuria, flank pain, mass — 'classic triad'), upper urinary tract TCC (renal pelvis, ureter); Benign urological — urolithiasis (usually painful), BPH (common in elderly men), urethral stricture; Infective — UTI, pyelonephritis, TB of the urinary tract; Anticoagulation — warfarin, DOACs (haematuria may be the presenting symptom of underlying malignancy unmasked by anticoagulation); Renal parenchymal — IgA nephropathy, thin basement membrane disease, Alport syndrome (red cell casts on microscopy); Trauma; Radiation cystitis (after pelvic radiotherapy). Never attribute haematuria to anticoagulation alone without full investigation.
Key point
Visible haematuria differential: bladder tumour, renal tumour, stones, UTI, BPH, anticoagulation, glomerulonephritis — never attribute haematuria to anticoagulants alone without full urological work-up.
Question 3 · Clot Retention Management
Correct answer: Insert a large-bore three-way catheter (22–24Fr), perform manual bladder washout to evacuate clots, then commence continuous bladder irrigation (CBI) with normal saline
Why
Clot retention requires a large-bore three-way (3-way) catheter (22–24Fr Foley) — a standard 14Fr catheter will block with clots and is inadequate. After insertion: perform manual bladder washout with a bladder syringe using normal saline to break up and evacuate clots (this may need to be vigorous). Then connect to continuous bladder irrigation (CBI) — a continuous saline drip into the bladder to prevent clot formation and keep the urine clear. Monitor: urine output from the drainage port, rate of CBI (titrate to keep drainage clear/pale pink), and blood transfusion requirements (check FBC). If the bleeding does not settle with CBI or if the patient becomes haemodynamically unstable, urgent cystoscopy + diathermy or embolisation may be required. Cystoscopy is not performed first without catheter decompression.
Key point
Clot retention: insert a large-bore three-way catheter (22–24Fr), manual washout to evacuate clots, then start continuous bladder irrigation (CBI) with normal saline.
Question 4 · Referral Criteria
Correct answer: NICE 2-week wait (2WW) urgent cancer referral to urology — visible haematuria in a patient over 45 without UTI meets criteria
Why
According to NICE NG12 (2015, updated 2023), the following criteria trigger a 2-week wait (2WW) urgent suspected cancer referral to urology: Unexplained visible haematuria without UTI in patients aged ≥45 years; Visible haematuria that persists or recurs after successful UTI treatment; Non-visible haematuria in patients aged ≥60 with dysuria or raised WCC on blood test. Colin is 68 with painless visible haematuria — this clearly meets 2WW criteria. The resolution of haematuria after catheterisation does not reduce urgency — bladder tumours often bleed intermittently. Routine referral would be inappropriate and risks delayed diagnosis. Nephrology/renal biopsy may be needed if a glomerular cause is suspected (RBC casts, proteinuria, renal impairment), but this is not the priority here.
Key point
NICE NG12: visible haematuria in patients ≥45 without UTI = 2-week wait urgent urology referral — resolution of haematuria does not reduce urgency.
Question 5 · Investigation Pathway
Correct answer: Flexible cystoscopy, upper tract imaging (USS kidneys and bladder ± CT urogram), and urine cytology
Why
The standard haematuria investigation pathway in UK urology clinics comprises: (1) Flexible cystoscopy — outpatient endoscopic examination of the urethra and bladder under local anaesthetic (lidocaine gel); directly visualises bladder tumours, the urethra, and bladder trigone; can take biopsies if indicated; (2) Upper tract imaging — USS kidneys and bladder is first-line and widely available; CT urogram (CTU) is performed if USS is inconclusive or upper tract TCC is suspected — it provides detailed imaging of the renal parenchyma and collecting system; (3) Urine cytology — detects exfoliated malignant cells; high specificity for high-grade bladder cancer but lower sensitivity for low-grade tumours. Together these three investigations form the haematuria triple assessment. Plain AXR is not diagnostic. MRI pelvis is used for staging confirmed bladder cancer, not primary investigation.
Key point
Haematuria triple assessment: flexible cystoscopy + upper tract imaging (USS/CT urogram) + urine cytology — these three tests together form the standard urology work-up.
Question 6 · Anticoagulated Patient with Haematuria
Correct answer: Visible haematuria in an anticoagulated patient requires full urological investigation — anticoagulants do not cause haematuria in isolation and may be unmasking an underlying malignancy
Why
A critical principle in haematuria management: anticoagulation does not cause haematuria — it may amplify bleeding from an underlying source, but a structural cause must always be excluded. Studies show that a significant proportion of anticoagulated patients with haematuria have an underlying malignancy or structural lesion (stones, BPH complication) as the source. Therefore, visible haematuria in an anticoagulated patient requires the same full urological investigation pathway — 2WW referral, flexible cystoscopy, upper tract imaging, and urine cytology. Do not stop anticoagulation empirically — this increases thromboembolic risk (e.g., stroke in a patient with AF) without clinical benefit. The bleeding risk-benefit balance of the anticoagulant should be reviewed with the prescribing physician, but investigation should not be delayed. Never accept 'anticoagulation' as the sole explanation for haematuria.
Key point
Anticoagulants do not cause haematuria — they amplify bleeding from an underlying lesion; always investigate haematuria fully in anticoagulated patients, do not attribute it to the drug.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.